Karyopharm Therapeutics | KPTI - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.52B 258M 2026-09
Abbott USD 11.66B 1.2B 2026-09
Amgen USD 5.69B 6B 2026-09
AstraZeneca USD 11.55B 674M 2026-09
BioCryst Pharmaceuticals USD -397.38M 517.17M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
GlaxoSmithKline GBP 6.03B 227M 2026-09
Incyte USD 5.64B 4.67B 2026-09
J&J USD 18.93B 1.09B 2026-09
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 10.75B 5.02B 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 9.88B 325M 2026-09
Novartis USD 13.19B 3.9B 2026-09
Pfizer USD 89B 3.81B 2026-09
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Takeda JPY 981.78B 36.71B 2026-09
Tectonic Therapeutic USD 24.22M 3.08M 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Xencor USD 87.82M 5.44M 2026-06